LIVIVO - Search results -

Search results

Result 1 - 5 of total 5

Search options

Article: Exome sequencing identifies

medRxiv : the preprint server for health sciences

2024

Abstract: Rare, germline loss-of-function variants in a handful of genes that encode DNA repair proteins have been shown to be associated with epithelial ovarian cancer with a stronger association for the high-grade serous hiostotype. The aim of this study was to ... ...

Abstract	Rare, germline loss-of-function variants in a handful of genes that encode DNA repair proteins have been shown to be associated with epithelial ovarian cancer with a stronger association for the high-grade serous hiostotype. The aim of this study was to collate exome sequencing data from multiple epithelial ovarian cancer case cohorts and controls in order to systematically evaluate the role of coding, loss-of-function variants across the genome in epithelial ovarian cancer risk. We assembled exome data for a total of 2,573 non-mucinous cases (1,876 high-grade serous and 697 non-high grade serous) and 13,925 controls. Harmonised variant calling and quality control filtering was applied across the different data sets. We carried out a gene-by-gene simple burden test for association of rare loss-of-function variants (minor allele frequency < 0.1%) with all non-mucinous ovarian cancer, high grade serous ovarian cancer and non-high grade serous ovarian cancer using logistic regression adjusted for the top four principal components to account for cryptic population structure and genetic ancestry. Seven of the top 10 associated genes were associations of the known ovarian cancer susceptibility genes
Language	English
Publishing date	2024-04-03
Publishing country	United States
Document type	Preprint
DOI	10.1101/2024.04.02.24304968
Database	MEDical Literature Analysis and Retrieval System OnLINE

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation.

Candido Dos Reis, Francisco J / Wishart, Gordon C / Dicks, Ed M / Greenberg, David / Rashbass, Jem / Schmidt, Marjanka K / van den Broek, Alexandra J / Ellis, Ian O / Green, Andrew / Rakha, Emad / Maishman, Tom / Eccles, Diana M / Pharoah, Paul D P

Breast cancer research : BCR

2017 Volume 19, Issue 1, Page(s) 58

Abstract: Background: PREDICT is a breast cancer prognostic and treatment benefit model implemented online. The overall fit of the model has been good in multiple independent case series, but PREDICT has been shown to underestimate breast cancer specific ... ...

Abstract	Background: PREDICT is a breast cancer prognostic and treatment benefit model implemented online. The overall fit of the model has been good in multiple independent case series, but PREDICT has been shown to underestimate breast cancer specific mortality in women diagnosed under the age of 40. Another limitation is the use of discrete categories for tumour size and node status resulting in 'step' changes in risk estimates on moving between categories. We have refitted the PREDICT prognostic model using the original cohort of cases from East Anglia with updated survival time in order to take into account age at diagnosis and to smooth out the survival function for tumour size and node status. Methods: Multivariable Cox regression models were used to fit separate models for ER negative and ER positive disease. Continuous variables were fitted using fractional polynomials and a smoothed baseline hazard was obtained by regressing the baseline cumulative hazard for each patients against time using fractional polynomials. The fit of the prognostic models were then tested in three independent data sets that had also been used to validate the original version of PREDICT. Results: In the model fitting data, after adjusting for other prognostic variables, there is an increase in risk of breast cancer specific mortality in younger and older patients with ER positive disease, with a substantial increase in risk for women diagnosed before the age of 35. In ER negative disease the risk increases slightly with age. The association between breast cancer specific mortality and both tumour size and number of positive nodes was non-linear with a more marked increase in risk with increasing size and increasing number of nodes in ER positive disease. The overall calibration and discrimination of the new version of PREDICT (v2) was good and comparable to that of the previous version in both model development and validation data sets. However, the calibration of v2 improved over v1 in patients diagnosed under the age of 40. Conclusions: The PREDICT v2 is an improved prognostication and treatment benefit model compared with v1. The online version should continue to aid clinical decision making in women with early breast cancer.
MeSH term(s)	Adult ; Breast/pathology ; Breast Neoplasms/epidemiology ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Estrogen Receptor alpha/genetics ; Female ; Humans ; Prognosis ; Proportional Hazards Models
Chemical Substances	Estrogen Receptor alpha
Language	English
Publishing date	2017-05-22
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2015059-3
ISSN	1465-542X ; 1465-5411
ISSN (online)	1465-542X
ISSN	1465-5411
DOI	10.1186/s13058-017-0852-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5494: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Population-based targeted sequencing of 54 candidate genes identifies

Song, Honglin / Dicks, Ed M / Tyrer, Jonathan / Intermaggio, Maria / Chenevix-Trench, Georgia / Bowtell, David D / Traficante, Nadia / Group, Aocs / Brenton, James / Goranova, Teodora / Hosking, Karen / Piskorz, Anna / van Oudenhove, Elke / Doherty, Jen / Harris, Holly R / Rossing, Mary Anne / Duerst, Matthias / Dork, Thilo / Bogdanova, Natalia V /

Modugno, Francesmary / Moysich, Kirsten / Odunsi, Kunle / Ness, Roberta / Karlan, Beth Y / Lester, Jenny / Jensen, Allan / Krüger Kjaer, Susanne / Høgdall, Estrid / Campbell, Ian G / Lázaro, Conxi / Pujara, Miguel Angel / Cunningham, Julie / Vierkant, Robert / Winham, Stacey J / Hildebrandt, Michelle / Huff, Chad / Li, Donghui / Wu, Xifeng / Yu, Yao / Permuth, Jennifer B / Levine, Douglas A / Schildkraut, Joellen M / Riggan, Marjorie J / Berchuck, Andrew / Webb, Penelope M / Group, Opal Study / Cybulski, Cezary / Gronwald, Jacek / Jakubowska, Anna / Lubinski, Jan / Alsop, Jennifer / Harrington, Patricia / Chan, Isaac / Menon, Usha / Pearce, Celeste L / Wu, Anna H / de Fazio, Anna / Kennedy, Catherine J / Goode, Ellen / Ramus, Susan / Gayther, Simon / Pharoah, Paul

Journal of medical genetics

2020 Volume 58, Issue 5, Page(s) 305–313

Abstract: Purpose: The known epithelial ovarian cancer (EOC) susceptibility genes account for less than 50% of the heritable risk of ovarian cancer suggesting that other susceptibility genes exist. The aim of this study was to evaluate the contribution to ovarian ...

Abstract	Purpose: The known epithelial ovarian cancer (EOC) susceptibility genes account for less than 50% of the heritable risk of ovarian cancer suggesting that other susceptibility genes exist. The aim of this study was to evaluate the contribution to ovarian cancer susceptibility of rare deleterious germline variants in a set of candidate genes. Methods: We sequenced the coding region of 54 candidate genes in 6385 invasive EOC cases and 6115 controls of broad European ancestry. Genes with an increased frequency of putative deleterious variants in cases versus controls were further examined in an independent set of 14 135 EOC cases and 28 655 controls from the Ovarian Cancer Association Consortium and the UK Biobank. For each gene, we estimated the EOC risks and evaluated associations between germline variant status and clinical characteristics. Results: The ORs associated for high-grade serous ovarian cancer were 3.01 for Conclusions: We have found strong evidence that carriers of
MeSH term(s)	Case-Control Studies ; Fanconi Anemia Complementation Group N Protein/genetics ; Female ; Genetic Predisposition to Disease ; Genetic Variation ; Humans ; Ovarian Neoplasms/genetics ; Risk Assessment
Chemical Substances	Fanconi Anemia Complementation Group N Protein ; PALB2 protein, human
Language	English
Publishing date	2020-06-16
Publishing country	England
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
ZDB-ID	220881-7
ISSN	1468-6244 ; 0022-2593
ISSN (online)	1468-6244
ISSN	0022-2593
DOI	10.1136/jmedgenet-2019-106739
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 177: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer.

Winham, Stacey J / Pirie, Ailith / Chen, Yian Ann / Larson, Melissa C / Fogarty, Zachary C / Earp, Madalene A / Anton-Culver, Hoda / Bandera, Elisa V / Cramer, Daniel / Doherty, Jennifer A / Goodman, Marc T / Gronwald, Jacek / Karlan, Beth Y / Kjaer, Susanne K / Levine, Douglas A / Menon, Usha / Ness, Roberta B / Pearce, Celeste L / Pejovic, Tanja /

Rossing, Mary Anne / Wentzensen, Nicolas / Bean, Yukie T / Bisogna, Maria / Brinton, Louise A / Carney, Michael E / Cunningham, Julie M / Cybulski, Cezary / deFazio, Anna / Dicks, Ed M / Edwards, Robert P / Gayther, Simon A / Gentry-Maharaj, Aleksandra / Gore, Martin / Iversen, Edwin S / Jensen, Allan / Johnatty, Sharon E / Lester, Jenny / Lin, Hui-Yi / Lissowska, Jolanta / Lubinski, Jan / Menkiszak, Janusz / Modugno, Francesmary / Moysich, Kirsten B / Orlow, Irene / Pike, Malcolm C / Ramus, Susan J / Song, Honglin / Terry, Kathryn L / Thompson, Pamela J / Tyrer, Jonathan P / van den Berg, David J / Vierkant, Robert A / Vitonis, Allison F / Walsh, Christine / Wilkens, Lynne R / Wu, Anna H / Yang, Hannah / Ziogas, Argyrios / Berchuck, Andrew / Chenevix-Trench, Georgia / Schildkraut, Joellen M / Permuth-Wey, Jennifer / Phelan, Catherine M / Pharoah, Paul D P / Fridley, Brooke L / Sellers, Thomas A / Goode, Ellen L

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

2016 Volume 25, Issue 3, Page(s) 446–454

Abstract: Background: While numerous susceptibility loci for epithelial ovarian cancer (EOC) have been identified, few associations have been reported with overall survival. In the absence of common prognostic genetic markers, we hypothesize that rare coding ... ...

Abstract	Background: While numerous susceptibility loci for epithelial ovarian cancer (EOC) have been identified, few associations have been reported with overall survival. In the absence of common prognostic genetic markers, we hypothesize that rare coding variants may be associated with overall EOC survival and assessed their contribution in two exome-based genotyping projects of the Ovarian Cancer Association Consortium (OCAC). Methods: The primary patient set (Set 1) included 14 independent EOC studies (4,293 patients) and 227,892 variants, and a secondary patient set (Set 2) included six additional EOC studies (1,744 patients) and 114,620 variants. Because power to detect rare variants individually is reduced, gene-level tests were conducted. Sets were analyzed separately at individual variants and by gene, and then combined with meta-analyses (73,203 variants and 13,163 genes overlapped). Results: No individual variant reached genome-wide statistical significance. A SNP previously implicated to be associated with EOC risk and, to a lesser extent, survival, rs8170, showed the strongest evidence of association with survival and similar effect size estimates across sets (Pmeta = 1.1E-6, HRSet1 = 1.17, HRSet2 = 1.14). Rare variants in ATG2B, an autophagy gene important for apoptosis, were significantly associated with survival after multiple testing correction (Pmeta = 1.1E-6; Pcorrected = 0.01). Conclusions: Common variant rs8170 and rare variants in ATG2B may be associated with EOC overall survival, although further study is needed. Impact: This study represents the first exome-wide association study of EOC survival to include rare variant analyses, and suggests that complementary single variant and gene-level analyses in large studies are needed to identify rare variants that warrant follow-up study. Cancer Epidemiol Biomarkers Prev; 25(3); 446-54. ©2016 AACR.
MeSH term(s)	Exome ; Female ; Genotype ; Humans ; Middle Aged ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/mortality ; Survival Rate
Language	English
Publishing date	2016-01-08
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
ZDB-ID	1153420-5
ISSN	1538-7755 ; 1055-9965
ISSN (online)	1538-7755
ISSN	1055-9965
DOI	10.1158/1055-9965.EPI-15-0240
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3693: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.

Hollestelle, Antoinette / van der Baan, Frederieke H / Berchuck, Andrew / Johnatty, Sharon E / Aben, Katja K / Agnarsson, Bjarni A / Aittomäki, Kristiina / Alducci, Elisa / Andrulis, Irene L / Anton-Culver, Hoda / Antonenkova, Natalia N / Antoniou, Antonis C / Apicella, Carmel / Arndt, Volker / Arnold, Norbert / Arun, Banu K / Arver, Brita / Ashworth, Alan / Baglietto, Laura /

Balleine, Rosemary / Bandera, Elisa V / Barrowdale, Daniel / Bean, Yukie T / Beckmann, Lars / Beckmann, Matthias W / Benitez, Javier / Berger, Andreas / Berger, Raanan / Beuselinck, Benoit / Bisogna, Maria / Bjorge, Line / Blomqvist, Carl / Bogdanova, Natalia V / Bojesen, Anders / Bojesen, Stig E / Bolla, Manjeet K / Bonanni, Bernardo / Brand, Judith S / Brauch, Hiltrud / Brenner, Hermann / Brinton, Louise / Brooks-Wilson, Angela / Bruinsma, Fiona / Brunet, Joan / Brüning, Thomas / Budzilowska, Agnieszka / Bunker, Clareann H / Burwinkel, Barbara / Butzow, Ralf / Buys, Saundra S / Caligo, Maria A / Campbell, Ian / Carter, Jonathan / Chang-Claude, Jenny / Chanock, Stephen J / Claes, Kathleen B M / Collée, J Margriet / Cook, Linda S / Couch, Fergus J / Cox, Angela / Cramer, Daniel / Cross, Simon S / Cunningham, Julie M / Cybulski, Cezary / Czene, Kamila / Damiola, Francesca / Dansonka-Mieszkowska, Agnieszka / Darabi, Hatef / de la Hoya, Miguel / deFazio, Anna / Dennis, Joseph / Devilee, Peter / Dicks, Ed M / Diez, Orland / Doherty, Jennifer A / Domchek, Susan M / Dorfling, Cecilia M / Dörk, Thilo / Silva, Isabel Dos Santos / du Bois, Andreas / Dumont, Martine / Dunning, Alison M / Duran, Mercedes / Easton, Douglas F / Eccles, Diana / Edwards, Robert P / Ehrencrona, Hans / Ejlertsen, Bent / Ekici, Arif B / Ellis, Steve D / Engel, Christoph / Eriksson, Mikael / Fasching, Peter A / Feliubadalo, Lidia / Figueroa, Jonine / Flesch-Janys, Dieter / Fletcher, Olivia / Fontaine, Annette / Fortuzzi, Stefano / Fostira, Florentia / Fridley, Brooke L / Friebel, Tara / Friedman, Eitan / Friel, Grace / Frost, Debra / Garber, Judy / García-Closas, Montserrat / Gayther, Simon A / Gentry-Maharaj, Aleksandra / Gerdes, Anne-Marie / Giles, Graham G / Glasspool, Rosalind / Glendon, Gord / Godwin, Andrew K / Goodman, Marc T / Gore, Martin / Greene, Mark H / Grip, Mervi / Gronwald, Jacek / Gschwantler Kaulich, Daphne / Guénel, Pascal / Guzman, Starr R / Haeberle, Lothar / Haiman, Christopher A / Hall, Per / Halverson, Sandra L / Hamann, Ute / Hansen, Thomas V O / Harter, Philipp / Hartikainen, Jaana M / Healey, Sue / Hein, Alexander / Heitz, Florian / Henderson, Brian E / Herzog, Josef / T Hildebrandt, Michelle A / Høgdall, Claus K / Høgdall, Estrid / Hogervorst, Frans B L / Hopper, John L / Humphreys, Keith / Huzarski, Tomasz / Imyanitov, Evgeny N / Isaacs, Claudine / Jakubowska, Anna / Janavicius, Ramunas / Jaworska, Katarzyna / Jensen, Allan / Jensen, Uffe Birk / Johnson, Nichola / Jukkola-Vuorinen, Arja / Kabisch, Maria / Karlan, Beth Y / Kataja, Vesa / Kauff, Noah / Kelemen, Linda E / Kerin, Michael J / Kiemeney, Lambertus A / Kjaer, Susanne K / Knight, Julia A / Knol-Bout, Jacoba P / Konstantopoulou, Irene / Kosma, Veli-Matti / Krakstad, Camilla / Kristensen, Vessela / Kuchenbaecker, Karoline B / Kupryjanczyk, Jolanta / Laitman, Yael / Lambrechts, Diether / Lambrechts, Sandrina / Larson, Melissa C / Lasa, Adriana / Laurent-Puig, Pierre / Lazaro, Conxi / Le, Nhu D / Le Marchand, Loic / Leminen, Arto / Lester, Jenny / Levine, Douglas A / Li, Jingmei / Liang, Dong / Lindblom, Annika / Lindor, Noralane / Lissowska, Jolanta / Long, Jirong / Lu, Karen H / Lubinski, Jan / Lundvall, Lene / Lurie, Galina / Mai, Phuong L / Mannermaa, Arto / Margolin, Sara / Mariette, Frederique / Marme, Frederik / Martens, John W M / Massuger, Leon F A G / Maugard, Christine / Mazoyer, Sylvie / McGuffog, Lesley / McGuire, Valerie / McLean, Catriona / McNeish, Iain / Meindl, Alfons / Menegaux, Florence / Menéndez, Primitiva / Menkiszak, Janusz / Menon, Usha / Mensenkamp, Arjen R / Miller, Nicola / Milne, Roger L / Modugno, Francesmary / Montagna, Marco / Moysich, Kirsten B / Müller, Heiko / Mulligan, Anna Marie / Muranen, Taru A / Narod, Steven A / Nathanson, Katherine L / Ness, Roberta B / Neuhausen, Susan L / Nevanlinna, Heli / Neven, Patrick / Nielsen, Finn C / Nielsen, Sune F / Nordestgaard, Børge G / Nussbaum, Robert L / Odunsi, Kunle / Offit, Kenneth / Olah, Edith / Olopade, Olufunmilayo I / Olson, Janet E / Olson, Sara H / Oosterwijk, Jan C / Orlow, Irene / Orr, Nick / Orsulic, Sandra / Osorio, Ana / Ottini, Laura / Paul, James / Pearce, Celeste L / Pedersen, Inge Sokilde / Peissel, Bernard / Pejovic, Tanja / Pelttari, Liisa M / Perkins, Jo / Permuth-Wey, Jenny / Peterlongo, Paolo / Peto, Julian / Phelan, Catherine M / Phillips, Kelly-Anne / Piedmonte, Marion / Pike, Malcolm C / Platte, Radka / Plisiecka-Halasa, Joanna / Poole, Elizabeth M / Poppe, Bruce / Pylkäs, Katri / Radice, Paolo / Ramus, Susan J / Rebbeck, Timothy R / Reed, Malcolm W R / Rennert, Gad / Risch, Harvey A / Robson, Mark / Rodriguez, Gustavo C / Romero, Atocha / Rossing, Mary Anne / Rothstein, Joseph H / Rudolph, Anja / Runnebaum, Ingo / Salani, Ritu / Salvesen, Helga B / Sawyer, Elinor J / Schildkraut, Joellen M / Schmidt, Marjanka K / Schmutzler, Rita K / Schneeweiss, Andreas / Schoemaker, Minouk J / Schrauder, Michael G / Schumacher, Fredrick / Schwaab, Ira / Scuvera, Giulietta / Sellers, Thomas A / Severi, Gianluca / Seynaeve, Caroline M / Shah, Mitul / Shrubsole, Martha / Siddiqui, Nadeem / Sieh, Weiva / Simard, Jacques / Singer, Christian F / Sinilnikova, Olga M / Smeets, Dominiek / Sohn, Christof / Soller, Maria / Song, Honglin / Soucy, Penny / Southey, Melissa C / Stegmaier, Christa / Stoppa-Lyonnet, Dominique / Sucheston, Lara / Swerdlow, Anthony / Tangen, Ingvild L / Tea, Muy-Kheng / Teixeira, Manuel R / Terry, Kathryn L / Terry, Mary Beth / Thomassen, Mads / Thompson, Pamela J / Tihomirova, Laima / Tischkowitz, Marc / Toland, Amanda Ewart / Tollenaar, Rob A E M / Tomlinson, Ian / Torres, Diana / Truong, Thérèse / Tsimiklis, Helen / Tung, Nadine / Tworoger, Shelley S / Tyrer, Jonathan P / Vachon, Celine M / Van 't Veer, Laura J / van Altena, Anne M / Van Asperen, C J / van den Berg, David / van den Ouweland, Ans M W / van Doorn, Helena C / Van Nieuwenhuysen, Els / van Rensburg, Elizabeth J / Vergote, Ignace / Verhoef, Senno / Vierkant, Robert A / Vijai, Joseph / Vitonis, Allison F / von Wachenfeldt, Anna / Walsh, Christine / Wang, Qin / Wang-Gohrke, Shan / Wappenschmidt, Barbara / Weischer, Maren / Weitzel, Jeffrey N / Weltens, Caroline / Wentzensen, Nicolas / Whittemore, Alice S / Wilkens, Lynne R / Winqvist, Robert / Wu, Anna H / Wu, Xifeng / Yang, Hannah P / Zaffaroni, Daniela / Pilar Zamora, M / Zheng, Wei / Ziogas, Argyrios / Chenevix-Trench, Georgia / Pharoah, Paul D P / Rookus, Matti A / Hooning, Maartje J / Goode, Ellen L

Gynecologic oncology

2015 Volume 141, Issue 2, Page(s) 386–401

Abstract: Objective: Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as with survival ... ...

Abstract	Objective: Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as with survival time. However, prior studies, emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated ovarian and breast cancer risks as well as clinical outcome associated with rs61764370. Methods: Centralized genotyping and analysis were performed for 140,012 women enrolled in the Ovarian Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), the Breast Cancer Association Consortium (33,530 breast cancer patients; 37,640 controls), and the Consortium of Modifiers of BRCA1 and BRCA2 (14,765 BRCA1 and 7904 BRCA2 mutation carriers). Results: We found no association with risk of ovarian cancer (OR=0.99, 95% CI 0.94-1.04, p=0.74) or breast cancer (OR=0.98, 95% CI 0.94-1.01, p=0.19) and results were consistent among mutation carriers (BRCA1, ovarian cancer HR=1.09, 95% CI 0.97-1.23, p=0.14, breast cancer HR=1.04, 95% CI 0.97-1.12, p=0.27; BRCA2, ovarian cancer HR=0.89, 95% CI 0.71-1.13, p=0.34, breast cancer HR=1.06, 95% CI 0.94-1.19, p=0.35). Null results were also obtained for associations with overall survival following ovarian cancer (HR=0.94, 95% CI 0.83-1.07, p=0.38), breast cancer (HR=0.96, 95% CI 0.87-1.06, p=0.38), and all other previously-reported associations. Conclusions: rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers. Therefore, genotyping this variant has no clinical utility related to the prediction or management of these cancers.
MeSH term(s)	Breast Neoplasms/enzymology ; Breast Neoplasms/genetics ; Carcinoma, Ovarian Epithelial ; Female ; Humans ; Neoplasms, Glandular and Epithelial/enzymology ; Neoplasms, Glandular and Epithelial/genetics ; Ovarian Neoplasms/enzymology ; Ovarian Neoplasms/genetics ; Proto-Oncogene Proteins p21(ras)/genetics
Chemical Substances	KRAS protein, human ; Proto-Oncogene Proteins p21(ras) (EC 3.6.5.2)
Language	English
Publishing date	2015-05-02
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	801461-9
ISSN	1095-6859 ; 0090-8258
ISSN (online)	1095-6859
ISSN	0090-8258
DOI	10.1016/j.ygyno.2015.04.034
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 885: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

Search results

Search options

Article: Exome sequencing identifies

More links

Kategorien

Inter-library loan at ZB MED

Article ; Online: An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation.

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article ; Online: Population-based targeted sequencing of 54 candidate genes identifies

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article ; Online: Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer.

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article ; Online: No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito